November 18, 2013

Company Name: Sysmex Corporation
Company Representative: Hisashi Ietsugu, Chairman and CEO
Code: 6869
Contact: Yukitoshi Kamao, Executive Officer, Corporate Business Administration
Phone: 078-265-0500

(Corrections and Corrections to Numerical Data)

Partial Correction to Summary of Consolidated Financial Results for the First Six Months of the Fiscal Year Ending March 31, 2014

Sysmex Corporation hereby provides notice of a partial correction the "Summary of Consolidated Financial Results for the First Six Months of the Fiscal Year Ending March 31, 2014," announced on November 5, 2013, as described below. As numerical data has also been corrected, we will send the post-correction data. The correction is indicated below in **underlined** text.

1. Contents of the Corrections

1)

1. Financial Performance

1) Performance analysis

(1) Japan

(3) EMEA

(Before Correction)

(1) Japan

Performance in Japan improved, mainly in the hemostasis and urinalysis fields, as we continued to persevere in promoting solution proposals. However, sales in the "Japan" segment decreased 3.4% year on year, to ¥19,460 million, because of the conversion of our South Korean distributor to a subsidiary, as sales to external customers formerly recorded in the "Japan" segment were shifted to the "Asia Pacific" segment during the first three months of the fiscal year.

On the profit front, such factors as the expansion of export sales to Group companies led to an 83.4% surge in operating income, to ¥9,340 million.

(3) EMEA

Efforts to enhance our direct sales and support services led to robust sales in Russia and emerging markets, and we acquired new bid projects in Spain, resulting in favorable sales, centered on the hematology field. Segment sales consequently rose 34.5%, to ¥23,680 million.

Operating income jumped 47.1%, to ¥3,878 million, as the expansion in sales outpaced the rise in selling, general and administrative expenses accompanying our business expansion.

(After Correction)

(1) Japan

Performance in Japan improved, mainly in the hemostasis and urinalysis fields, as we continued to persevere in promoting solution proposals. However, sales in the “Japan” segment decreased 3.4% year on year, to ¥19,460 million, because of the conversion of our South Korean distributor to a subsidiary, as sales to external customers formerly recorded in the “Japan” segment were shifted to the “Asia Pacific” segment during the first three months of the fiscal year.

On the profit front, such factors as the expansion of export sales to Group companies led to an 81.1% surge in operating income, to ¥9,224million.

(3) EMEA

Efforts to enhance our direct sales and support services led to robust sales in Russia and emerging markets, and we acquired new bid projects in Spain, resulting in favorable sales, centered on the hematology field. Segment sales consequently rose 34.5%, to ¥23,680 million.

Operating income jumped 56.1%, to ¥4,116 million, as the expansion in sales outpaced the rise in selling, general and administrative expenses accompanying our business expansion.

2)

Notes to the consolidated financial statements

(Segment information)

(Before Correction)

Ⅱ Information on sales and income by geographic segment reported

1. Six months ended September 30, 2013

(Unit: Millions of Yen)

	Japan	Americas	EMEA	China	Asia Pacific	Total	Reconciliations	Consolidated
Sales and Operating income								
Sales								
Net Sales to outside customers	19,460	17,242	23,680	17,248	6,446	84,079	—	84,079
Inter-area transfer	29,037	2	351	2	80	29,473	(29,473)	—
Total net sales	48,498	17,245	24,031	17,251	6,526	113,553	(29,473)	84,079
Operating income	9,340	726	3,878	1,947	798	16,691	(2,978)	13,712

Note:

1. Segment income reconciliations of minus ¥2,978 million include ¥64 million for the elimination of intersegment transfers, a negative ¥2,942 million in inventory adjustments and a minus ¥101 million in adjustments for noncurrent assets.
2. Segment income is adjusted to operating income on the consolidated statements of income.
3. The previous segment grouping called “Europe” actually included operations extending from Europe and including the Middle East and Africa. To making the naming more accurate, however, from the first quarter of the fiscal year ending March 31, 2014, the segment’s name was changed to “EMEA.” This naming change does not indicate any revision in the countries or regions accounted for by the grouping. In accordance with

this change, the first six months of the preceding fiscal year and the first six months of the fiscal year under review use the “EMEA” grouping.

(After Correction)

Ⅱ Information on sales and income by geographic segment reported

1. Six months ended September 30, 2013

(Unit: Millions of Yen)

	Japan	Americas	EMEA	China	Asia Pacific	Total	Reconciliations	Consolidated
Sales and Operating income								
Sales								
Net Sales to outside customers	19,460	17,242	23,680	17,248	6,446	84,079	—	84,079
Inter-area transfer	29,037	2	351	2	80	29,473	(29,473)	—
Total net sales	48,498	17,245	24,031	17,251	6,526	113,553	(29,473)	84,079
Operating income	9,224	726	4,116	1,947	798	16,813	(3,100)	13,712

Note:

1. Segment income reconciliations of minus ¥3,100 million include ¥64 million for the elimination of intersegment transfers, a negative ¥2,942 million in inventory adjustments and a minus ¥101 million in adjustments for noncurrent assets.
2. Segment income is adjusted to operating income on the consolidated statements of income.
3. The previous segment grouping called “Europe” actually included operations extending from Europe and including the Middle East and Africa. To making the naming more accurate, however, from the first quarter of the fiscal year ending March 31, 2014, the segment’s name was changed to “EMEA.” This naming change does not indicate any revision in the countries or regions accounted for by the grouping. In accordance with this change, the first six months of the preceding fiscal year and the first six months of the fiscal year under review use the “EMEA” grouping.

2. Reason for the Corrections

Revisions have been made to correct errors found in the segment information figures within the Summary of Consolidated Financial Results for the First Six Months of the Fiscal Year Ending March 31, 2014.